vs
Side-by-side financial comparison of Bio-Techne (TECH) and Walker & Dunlop, Inc. (WD). Click either name above to swap in a different company.
Walker & Dunlop, Inc. is the larger business by last-quarter revenue ($340.0M vs $295.9M, roughly 1.1× Bio-Techne). Bio-Techne runs the higher net margin — 12.8% vs -12.9%, a 25.8% gap on every dollar of revenue. On growth, Walker & Dunlop, Inc. posted the faster year-over-year revenue change (-0.4% vs -6.4%). Over the past eight quarters, Walker & Dunlop, Inc.'s revenue compounded faster (22.1% CAGR vs 4.2%).
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
Walker & Dunlop, Inc. is one of the largest commercial real estate finance and advisory services firms in the United States and internationally.
TECH vs WD — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $295.9M | $340.0M |
| Net Profit | $38.0M | $-13.9M |
| Gross Margin | 64.6% | — |
| Operating Margin | 18.4% | -17.2% |
| Net Margin | 12.8% | -12.9% |
| Revenue YoY | -6.4% | -0.4% |
| Net Profit YoY | 68.3% | -131.0% |
| EPS (diluted) | $0.24 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $295.9M | $340.0M | ||
| Q3 25 | — | $337.7M | ||
| Q2 25 | $317.0M | $319.2M | ||
| Q1 25 | $316.2M | $237.4M | ||
| Q4 24 | $297.0M | $341.5M | ||
| Q3 24 | $289.5M | $292.3M | ||
| Q2 24 | $306.1M | $270.7M | ||
| Q1 24 | $303.4M | $228.1M |
| Q4 25 | $38.0M | $-13.9M | ||
| Q3 25 | — | $33.5M | ||
| Q2 25 | $-17.7M | $34.0M | ||
| Q1 25 | $22.6M | $2.8M | ||
| Q4 24 | $34.9M | $44.8M | ||
| Q3 24 | $33.6M | $28.8M | ||
| Q2 24 | $40.6M | $22.7M | ||
| Q1 24 | $49.1M | $11.9M |
| Q4 25 | 64.6% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 62.7% | — | ||
| Q1 25 | 67.9% | — | ||
| Q4 24 | 65.3% | — | ||
| Q3 24 | 63.2% | — | ||
| Q2 24 | 66.4% | — | ||
| Q1 24 | 67.4% | — |
| Q4 25 | 18.4% | -17.2% | ||
| Q3 25 | — | 13.6% | ||
| Q2 25 | -7.5% | 14.5% | ||
| Q1 25 | 12.2% | 2.2% | ||
| Q4 24 | 16.0% | 15.3% | ||
| Q3 24 | 13.8% | 12.8% | ||
| Q2 24 | 15.0% | 10.4% | ||
| Q1 24 | 22.1% | 6.0% |
| Q4 25 | 12.8% | -12.9% | ||
| Q3 25 | — | 9.9% | ||
| Q2 25 | -5.6% | 10.6% | ||
| Q1 25 | 7.1% | 1.2% | ||
| Q4 24 | 11.7% | 13.1% | ||
| Q3 24 | 11.6% | 9.9% | ||
| Q2 24 | 13.3% | 8.4% | ||
| Q1 24 | 16.2% | 5.2% |
| Q4 25 | $0.24 | $-0.41 | ||
| Q3 25 | — | $0.98 | ||
| Q2 25 | $-0.11 | $0.99 | ||
| Q1 25 | $0.14 | $0.08 | ||
| Q4 24 | $0.22 | $1.32 | ||
| Q3 24 | $0.21 | $0.85 | ||
| Q2 24 | $0.26 | $0.67 | ||
| Q1 24 | $0.31 | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $172.9M | $299.3M |
| Total DebtLower is stronger | $260.0M | — |
| Stockholders' EquityBook value | $2.0B | $1.7B |
| Total Assets | $2.5B | $5.1B |
| Debt / EquityLower = less leverage | 0.13× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $172.9M | $299.3M | ||
| Q3 25 | — | $274.8M | ||
| Q2 25 | $162.2M | $233.7M | ||
| Q1 25 | $140.7M | $181.0M | ||
| Q4 24 | $177.5M | $279.3M | ||
| Q3 24 | $187.5M | $179.8M | ||
| Q2 24 | $152.9M | $208.1M | ||
| Q1 24 | $145.3M | $216.5M |
| Q4 25 | $260.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $346.0M | — | ||
| Q1 25 | $330.0M | — | ||
| Q4 24 | $300.0M | — | ||
| Q3 24 | $300.0M | — | ||
| Q2 24 | $319.0M | — | ||
| Q1 24 | $389.0M | — |
| Q4 25 | $2.0B | $1.7B | ||
| Q3 25 | — | $1.8B | ||
| Q2 25 | $1.9B | $1.8B | ||
| Q1 25 | $2.0B | $1.7B | ||
| Q4 24 | $2.1B | $1.7B | ||
| Q3 24 | $2.1B | $1.7B | ||
| Q2 24 | $2.1B | $1.7B | ||
| Q1 24 | $2.0B | $1.7B |
| Q4 25 | $2.5B | $5.1B | ||
| Q3 25 | — | $5.8B | ||
| Q2 25 | $2.6B | $4.7B | ||
| Q1 25 | $2.6B | $4.5B | ||
| Q4 24 | $2.7B | $4.4B | ||
| Q3 24 | $2.7B | $4.6B | ||
| Q2 24 | $2.7B | $4.2B | ||
| Q1 24 | $2.7B | $3.8B |
| Q4 25 | 0.13× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.18× | — | ||
| Q1 25 | 0.16× | — | ||
| Q4 24 | 0.14× | — | ||
| Q3 24 | 0.14× | — | ||
| Q2 24 | 0.15× | — | ||
| Q1 24 | 0.19× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-664.3M |
| Free Cash FlowOCF − Capex | — | $-680.1M |
| FCF MarginFCF / Revenue | — | -200.0% |
| Capex IntensityCapex / Revenue | — | 4.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-2.2B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-664.3M | ||
| Q3 25 | — | $-948.1M | ||
| Q2 25 | $98.2M | $-238.5M | ||
| Q1 25 | $41.1M | $-281.1M | ||
| Q4 24 | $84.3M | $129.4M | ||
| Q3 24 | $63.9M | $-202.0M | ||
| Q2 24 | $75.5M | $-237.8M | ||
| Q1 24 | $81.0M | $38.4M |
| Q4 25 | — | $-680.1M | ||
| Q3 25 | — | $-950.4M | ||
| Q2 25 | $93.3M | $-241.0M | ||
| Q1 25 | $31.0M | $-284.7M | ||
| Q4 24 | $77.5M | $116.4M | ||
| Q3 24 | $54.7M | $-204.0M | ||
| Q2 24 | $57.5M | $-241.7M | ||
| Q1 24 | $64.5M | $35.2M |
| Q4 25 | — | -200.0% | ||
| Q3 25 | — | -281.5% | ||
| Q2 25 | 29.4% | -75.5% | ||
| Q1 25 | 9.8% | -120.0% | ||
| Q4 24 | 26.1% | 34.1% | ||
| Q3 24 | 18.9% | -69.8% | ||
| Q2 24 | 18.8% | -89.3% | ||
| Q1 24 | 21.3% | 15.4% |
| Q4 25 | — | 4.6% | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | 1.5% | 0.8% | ||
| Q1 25 | 3.2% | 1.5% | ||
| Q4 24 | 2.3% | 3.8% | ||
| Q3 24 | 3.2% | 0.7% | ||
| Q2 24 | 5.9% | 1.4% | ||
| Q1 24 | 5.4% | 1.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | -28.34× | ||
| Q2 25 | — | -7.02× | ||
| Q1 25 | 1.82× | -102.07× | ||
| Q4 24 | 2.42× | 2.89× | ||
| Q3 24 | 1.90× | -7.01× | ||
| Q2 24 | 1.86× | -10.49× | ||
| Q1 24 | 1.65× | 3.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
WD
Segment breakdown not available.
